There has been a long history of cardiovascular research at the University of Mississippi Medical Center (UMMC). Much of this research has been conducted in the Department of Physiology where their efforts are directed toward developing a quantitative and integrated analysis of the cardiovascular and renal systems. In addition both basic and clinical research on hypertension and cardio-renal diseases at UMMC have expanded in various departments and programs such as Pharmacology, Biochemistry, Neurosciences, Medicine, Endocrinology, and Obstetrics and Gynecology. UMMC also serves as the Examination Center for the Jackson Heart Study that has a major focus on cardiovascular disease in African Americans. UMMC has also been a participant is several major clinical trials such as ALLHAT. Thus, UMMC has a diversity of basic, clinical, and population research programs in cardiovascular diseases. The main objective of the multidisciplinary Hypertension and Cardiorenal Diseases Research (HCDR) Training Program is to recruit, train, and mentor pre-doctoral and postdoctoral students in hypertension and cardiovascular and renal research so that they become the next generation of researchers in this field. To achieve this goal the Center for Excellence in Cardiovascular-Renal Research (CECR) at UMMC will provide a stimulating and productive mentoring environment for pre-doctoral and postdoctoral students. The HCDR Training Program not only capitalizes on the expertise of a strong group of basic science and clinical investigators in the field of cardiovascular and renal research at UMMC but also the resources provided by these established laboratories and the CECR core facilities.
The specific aims of this training grant proposal are as follows: 1. To train pre-doctoral students (3) in a multi-disciplinary approach in course work and research opportunities in hypertension and cardiovascular-renal disease research. 2. To provide postdoctoral students (5) multi-disciplinary training and mentoring in hypertension and cardiovascular-renal disease research 3. To recruit and train minority pre-doctoral and postdoctoral students in hypertension and cardiovascular- renal diseases research. Funding of the HCDR training program at UMMC would increase the quality and quantity of trainees in this multi-disciplinary program and greatly enhance our ability to train the next generation of biomedical scientists in hypertension and cardio-renal diseases research.

Public Health Relevance

Hypertension has long been recognized as a major risk factor for cardiovascular diseases, including coronary artery disease, heart failure and stroke, and for ESRD. In the southeastern United States, and especially in Mississippi, cardiovascular and renal diseases occur much more frequently than in the rest of the country. The objective of the multidisciplinary Hypertension and Cardiorenal Diseases Research (HCDR) Training Program is to recruit, train, and mentor pre-doctoral and postdoctoral students in cardiovascular and renal research so that they become the next generation of researchers in this field.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Institutional National Research Service Award (T32)
Project #
5T32HL105324-03
Application #
8316219
Study Section
NHLBI Institutional Training Mechanism Review Committee (NITM)
Program Officer
Scott, Jane
Project Start
2010-09-20
Project End
2015-08-31
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
3
Fiscal Year
2012
Total Cost
$386,603
Indirect Cost
$26,779
Name
University of Mississippi Medical Center
Department
Physiology
Type
Schools of Medicine
DUNS #
928824473
City
Jackson
State
MS
Country
United States
Zip Code
39216
Faulkner, Jessica L; Plenty, Nicole L; Wallace, Kedra et al. (2018) Selective inhibition of 20-hydroxyeicosatetraenoic acid lowers blood pressure in a rat model of preeclampsia. Prostaglandins Other Lipid Mediat 134:108-113
Mouton, Alan J; Rivera Gonzalez, Osvaldo J; Kaminski, Amanda R et al. (2018) Matrix metalloproteinase-12 as an endogenous resolution promoting factor following myocardial infarction. Pharmacol Res 137:252-258
Cunningham Jr, Mark W; Castillo, Javier; Ibrahim, Tarek et al. (2018) AT1-AA (Angiotensin II Type 1 Receptor Agonistic Autoantibody) Blockade Prevents Preeclamptic Symptoms in Placental Ischemic Rats. Hypertension 71:886-893
Taylor, Erin B; Barati, Michelle T; Powell, David W et al. (2018) Plasma Cell Depletion Attenuates Hypertension in an Experimental Model of Autoimmune Disease. Hypertension 71:719-728
Shekhar, Shashank; Cunningham, Mark W; Pabbidi, Mallikarjuna R et al. (2018) Targeting vascular inflammation in ischemic stroke: Recent developments on novel immunomodulatory approaches. Eur J Pharmacol 833:531-544
Mouton, Alan J; Rivera, Osvaldo J; Lindsey, Merry L (2018) Myocardial infarction remodeling that progresses to heart failure: a signaling misunderstanding. Am J Physiol Heart Circ Physiol 315:H71-H79
Eddy, Adrian C; Bidwell 3rd, Gene L; George, Eric M (2018) Pro-angiogenic therapeutics for preeclampsia. Biol Sex Differ 9:36
Ma, Yonggang; Mouton, Alan J; Lindsey, Merry L (2018) Cardiac macrophage biology in the steady-state heart, the aging heart, and following myocardial infarction. Transl Res 191:15-28
Mouton, Alan J; DeLeon-Pennell, Kristine Y; Rivera Gonzalez, Osvaldo J et al. (2018) Mapping macrophage polarization over the myocardial infarction time continuum. Basic Res Cardiol 113:26
Adeosun, Samuel O; Moore, Kyle H; Lang, David M et al. (2018) A Novel Fluorescence-Based Assay for the Measurement of Biliverdin Reductase Activity. React Oxyg Species (Apex) 5:35-45

Showing the most recent 10 out of 107 publications